Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

161.00 -1.00 (-0.62%)
Streaming Delayed Price Updated: 2:03 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
From BeiGene, Ltd.
Via Business Wire
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients
BeiGene Ltd (NASDAQ: BGNE) announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to... 
Via Benzinga
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Why BeiGene Stock Soared Today
A regulatory filing gave a sneak peek at the company's second-quarter sales. 
Via The Motley Fool
Topics Regulatory Compliance
Exposures Legal Regulatory
Chinese Stock Crash
For a second week in a row, we saw a big drop in stocks on Monday, while the Delta virus variant was blamed for the selloff last week, this week the cause is a big Beijing regulatory crackdown on... 
Via Talk Markets
62 Biggest Movers From Yesterday
Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma
Health Canada has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at... 
Via Benzinga
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
From BeiGene, Ltd.
Via Business Wire
Yellow Card
The price of oil fell about 1% today. 
Via Talk Markets
BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients
The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The... 
Via Benzinga
BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
From BeiGene, Ltd.
Via Business Wire
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
From BeiGene, Ltd.
Via Business Wire
PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer
PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership... 
Via Benzinga
Fireworks Display
The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked. 
Via Talk Markets
Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Is This Chinese Biopharma Stock Still a Buy?
The pharmaceutical company had a solid first quarter and boasts a nice pipeline. 
Via The Motley Fool
Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. The company is developing its own products and... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
From BeiGene, Ltd.
Via Business Wire
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Chicago Fed National... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
5 Stocks To Watch For June 21, 2021
Some of the stocks that may grab investor focus today are: Amazon.com, Inc. (NASDAQ: AMZN) will remain in focus with the company’s two-day Prime shopping event beginning... 
Via Benzinga
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics ​​​worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong... 
Via Talk Markets
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (... 
Via Benzinga
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
From BeiGene, Ltd.
Via Business Wire
BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.